Introduction to Idhifa (Enasidenib) 100mg
Idhifa (Enasidenib) 100mg is a prescription medicine used for the treatment of acute myeloid leukemia (AML) with specific genetic mutations in adult patients. It belongs to a class of targeted oncology drugs that inhibit the mutant isocitrate dehydrogenase-2 (IDH2) enzyme, helping to slow or stop the growth of abnormal leukemia cells.
Idhifa (Enasidenib) 100mg is classified under Prescription Medicines, Oncology Medicines, Targeted Cancer Therapy, and Oral Cancer Treatments. It contains Enasidenib, which works by blocking the abnormal IDH2 enzyme, allowing leukemia cells to mature normally and eventually die.
In some markets, Enacitib 100mg is available as a generic brand containing the same active ingredient Enasidenib, offering similar therapeutic effects under the supervision of a qualified healthcare professional.
What Is Idhifa (Enasidenib)?
Idhifa is the brand name for Enasidenib, an oral targeted therapy for AML patients with IDH2 mutations.
Enasidenib belongs to a class of medicines known as IDH2 inhibitors. These drugs specifically target leukemia cells carrying IDH2 mutations, promoting normal cell differentiation and reducing leukemia proliferation.
Generic versions such as Enacitib 100mg contain the same active compound and may be used depending on physician recommendation and regional availability.
Drug Class and Mechanism of Action
Enasidenib is classified as an IDH2 inhibitor with targeted antileukemic properties.
How Enasidenib Works
It works in several ways:
- Inhibits mutant IDH2 enzymes in leukemia cells
- Reduces production of the oncometabolite 2-hydroxyglutarate (2-HG)
- Promotes differentiation of immature leukemia cells into normal blood cells
- Slows progression of acute myeloid leukemia
Through these mechanisms, Enasidenib helps control abnormal blood cell proliferation and supports hematologic recovery.
How Idhifa Works in the Body
AML cells with IDH2 mutations produce excess 2-HG, which blocks normal cell differentiation. Idhifa restores normal differentiation pathways, allowing leukemia cells to mature and die naturally.
Key Actions of Enasidenib
- Inhibits abnormal IDH2 enzyme activity
- Promotes maturation of immature leukemia cells
- Reduces leukemia cell proliferation
- Supports restoration of normal blood cell function
Some generic versions such as Enacitib deliver the same active compound, allowing similar targeted cancer therapy under professional supervision.
Medical Uses of Idhifa (Enasidenib) 100mg
Idhifa 100mg is prescribed for adult patients with relapsed or refractory AML with IDH2 mutations.
Idhifa for Acute Myeloid Leukemia
Used in patients whose leukemia has returned or is resistant to prior therapies.
Potential Benefits
- Reduced leukemia cell proliferation
- Improved blood cell counts and function
- Potential for hematologic remission
- Targeted therapy with fewer systemic side effects compared to traditional chemotherapy
Idhifa for Targeted Cancer Therapy
Provides treatment specifically for IDH2-mutated AML, sparing normal cells.
Treatment Benefits
- Precision medicine approach to leukemia
- Minimizes damage to healthy cells
- Supports long-term disease management
Who Can Take Enacitib 100mg?
Because Enasidenib is a potent oncology medicine, treatment should always be supervised by a qualified hematologist or oncologist.
Eligibility Criteria
Patients may be prescribed Idhifa if they:
- Are diagnosed with relapsed or refractory AML with IDH2 mutation
- Have adequate liver and kidney function
- Can adhere to strict monitoring and follow-up protocols
Certain generic options such as Enacitib may also be considered depending on availability and physician decision.
Who Should Avoid Idhifa (Enasidenib) 100mg
Idhifa should NOT be used by:
- Individuals with hypersensitivity to Enasidenib
- Patients with severe liver impairment unless closely monitored
- Pregnant or breastfeeding women
Idhifa (Enasidenib) 100mg Dosage and Administration
Standard Dosage Guidelines
Typical dosage recommendations include:
- Idhifa 100mg taken orally once daily
- Tablets should be swallowed whole with water
- Can be taken with or without food
- Regular monitoring of blood counts and liver function is essential
Dosage Adjustments
Doctors may adjust the dose depending on:
- Liver function abnormalities
- Blood cell counts
- Individual response to therapy
Side Effects of Idhifa 100mg
Like all oncology medicines, Idhifa may cause side effects.
Common Side Effects
- Nausea and vomiting
- Fatigue
- Diarrhea or constipation
- Swelling of extremities
Serious Side Effects
- Differentiation syndrome (life-threatening in rare cases)
- Liver toxicity
- Low blood cell counts (anemia, neutropenia, thrombocytopenia)
Patients should report any unusual or severe symptoms to their doctor immediately.
Storage:
Store below 25°C in a cool, dry place, protected from moisture and light. Keep the tablets in their original packaging and out of reach of children.
Frequently Asked Questions (FAQs)
1. What is Idhifa (Enasidenib) 100mg used for?
It is used to treat relapsed or refractory acute myeloid leukemia in adults with IDH2 mutations.
2. Can Enacitib 100mg cure AML?
Idhifa is a targeted therapy that helps control AML and may induce remission, but complete cure depends on individual response and combination with other therapies.
3. Is Idhifa chemotherapy?
No. It is a targeted therapy that specifically inhibits the mutant IDH2 enzyme rather than traditional cytotoxic chemotherapy.
4. Can Enacitib be taken with food?
Yes. Idhifa can be taken with or without food.
5. Is Enacitib 100mg the same as Idhifa?
Enacitib 100mg contains Enasidenib, the same active ingredient found in Idhifa. Generic versions is available. for more info. contact on WhatsApp: https://wa.me/8801742433764
6. Do I need a prescription to buy Enacitib (Enasidenib) 100mg?
Yes. Enacitib 100mg is prescription-only and should be used under a qualified healthcare professional.
Medical Disclaimer
Disclaimer:
The information provided is for educational purposes only and should not be considered medical advice. Idhifa (Enasidenib) is a prescription oncology medicine and must be used under the supervision of a qualified hematologist or oncologist. Always consult your physician before starting, stopping, or changing any medication.
